Sanna Bastiano's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 14, 2023
- Accession no.
- 0001209191-23-009232
- Filed
- Feb 14, 2023
- Trade date
- Feb 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $33.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sanna BastianoCIK 0001829069 | Officer (EVP, Cell & Genetic Therapies) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | FTax withholdingDisposed | −902 | $294.33 | −$265,485.66 | 66,368 | Direct | |
| Feb 13, 2023 | Common Stock | FTax withholdingDisposed | −4,340 | $298.26 | −$1,294,448.4 | 62,028 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −113 | $300.39F2,F3 | −$33,944.07 | 61,915 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79).
Referenced by the price of 1 transaction in Table I.